See more : Jardine Matheson Holdings Limited (JAR.L) Income Statement Analysis – Financial Results
Complete financial analysis of YS Biopharma Co., Ltd. (YS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YS Biopharma Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- INternational CArbide Technology Co., Ltd. (4754.TWO) Income Statement Analysis – Financial Results
- The J. M. Smucker Company (SJM) Income Statement Analysis – Financial Results
- Environmental Control Center Co.,Ltd. (4657.T) Income Statement Analysis – Financial Results
- RATIONAL Aktiengesellschaft (RTLLF) Income Statement Analysis – Financial Results
- Xiamen King Long Motor Group Co., Ltd. (600686.SS) Income Statement Analysis – Financial Results
YS Biopharma Co., Ltd. (YS)
About YS Biopharma Co., Ltd.
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 687.20M | 502.95M | 257.02M |
| Cost of Revenue | 153.36M | 117.07M | 59.66M |
| Gross Profit | 533.84M | 385.88M | 197.36M |
| Gross Profit Ratio | 77.68% | 76.72% | 76.79% |
| Research & Development | 318.70M | 211.22M | 94.39M |
| General & Administrative | 81.76M | 107.05M | 138.89M |
| Selling & Marketing | 251.56M | 165.72M | 69.44M |
| SG&A | 333.32M | 272.77M | 208.33M |
| Other Expenses | -199.45K | -2.41M | -22.36M |
| Operating Expenses | 647.15M | 481.82M | 319.68M |
| Cost & Expenses | 800.51M | 598.89M | 379.33M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.86M | 2.72M | 29.69M |
| Depreciation & Amortization | 36.69M | 31.15M | 27.91M |
| EBITDA | -76.82M | -67.20M | -116.78M |
| EBITDA Ratio | -11.18% | -13.36% | -45.44% |
| Operating Income | -139.38M | -118.96M | -125.85M |
| Operating Income Ratio | -20.28% | -23.65% | -48.96% |
| Total Other Income/Expenses | -4.96M | 17.89M | -48.52M |
| Income Before Tax | -144.35M | -101.07M | -174.37M |
| Income Before Tax Ratio | -21.00% | -20.09% | -67.84% |
| Income Tax Expense | 1.13M | 4.94M | 17.45M |
| Net Income | -145.48M | -106.00M | -191.83M |
| Net Income Ratio | -21.17% | -21.08% | -74.64% |
| EPS | -1.56 | -1.15 | -2.08 |
| EPS Diluted | -1.56 | -1.15 | -2.08 |
| Weighted Avg Shares Out | 93.06M | 92.17M | 92.17M |
| Weighted Avg Shares Out (Dil) | 93.06M | 92.17M | 92.17M |
YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Results of Extraordinary General Meeting
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
Source: https://incomestatements.info
Category: Stock Reports